|
|
Post by hellodolly on May 17, 2022 5:08:45 GMT -5
MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products for people living with endocrine and orphan lung diseases, today announced that it has entered into an agreement with Zealand Pharma A/S (Nasdaq: ZEAL) to acquire V-Go® for $10 million, with additional sales-based milestones plus the cost of certain inventory. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.
“MannKind is passionate about being a leader in mealtime control to address this unmet need within the diabetes community,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “This acquisition strategically leverages our infrastructure in the diabetes space and positions MannKind’s endocrine business for additional growth.”
“This transaction is an important step forward in executing on the strategic changes we announced at the end of March, to find partners for our commercial products and refocus our priorities on R&D,” said Adam Steensberg, MD, Chief Executive Officer of Zealand Pharma. “We believe we have found the right partner to fully leverage the value of V-Go and ensure continued availability of the product by patients and prescribers.”
V-Go is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles. Designed to be patient-friendly, V-Go is worn like a patch and eliminates the need for taking multiple daily shots.
“The easy click-and-go mechanism of V-Go and its ability to be flexibly placed on your body each day aligns with our mission of providing products that allow patients living with diabetes to experience life without limits,” said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. “V-Go joins our ultra rapid-acting inhaled insulin product, Afrezza®, in expanding MannKind’s portfolio of products that change the way diabetes is treated.”
The acquisition of V-Go by MannKind is anticipated to close in May 2022, subject to the satisfaction of certain closing conditions.
|
|
|
|
Post by neil36 on May 17, 2022 5:12:01 GMT -5
|
|
|
|
Post by hellodolly on May 17, 2022 5:12:33 GMT -5
Fill, Wear & Go with V-Go®
V-Go is a once-daily insulin wearable, patch-like, device that helps provide blood sugar control for everyday lifestyles.1,2
Fill: First, fill V-Go with fast-acting insulin, as described in the V-Go Instructions For Use.2
Insulin is not included with a V-Go prescription. A separate prescription for a U100 fast-acting insulin is required to fill V-Go.
Wear: Place V-Go where insulin can be injected or infused such as the abdomen or the backside of an arm. The location can be changed based on your preference or clothing choice each day.2
Go: For 24-hours, including while you sleep, a continuous insulin infusion can help manage blood sugar levels. If needed, V-Go can provide an additional mealtime insulin dose with a click of a button.2
What is V-Go?
The V-Go series of Wearable Insulin Delivery Devices are indicated for continuous subcutaneous infusion of either 20 Units of Insulin (0.83 U/hr), 30 Units of insulin (1.25 U/hr) or 40 Units of insulin (1.67 U/hr) in one 24-hour time period and on-demand bolus dosing in 2 Unit increments (up to 36 Units per one 24-hour time period) in adults requiring insulin.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
V-Go is magnetic resonance (MR) unsafe. Remove V-Go before X-ray, MRI or CT scan and replace it with a new V-Go after the test is completed. Do not use other insulin products while on V-Go therapy unless instructed by your healthcare professional.
|
|
|
|
Post by hellodolly on May 17, 2022 5:14:42 GMT -5
About us Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other rare disease areas with significant unmet medical needs. Zealand employs more than 300 people in Denmark and the US and has a portfolio of medicines and product candidates, including license collaborations with Boehringer Ingelheim. Our pipeline focusing on gastrointestinal, metabolic and other specialty diseases where we believe that the present standard of care is inadequate and where we have the resources to advance our peptide-based product candidates into the later stages of clinical development, including registration and commercialization, while opportunistically considering partnership relationships that may arise. In addition, we are looking to focus our efforts on drug candidates that may qualify for orphan/rare disease status. Our research and development, organization is structured to enable dynamic collaboration across various functions and project teams at each stage of discovery and development, allowing us to advance promising opportunities quickly and take advantage of our extensive knowledge of peptide design and product development. We have a track record of successfully inventing and developing novel peptide-based product candidates. This success is based on our deep understanding of peptide chemistry and extensive experience in improving the therapeutic characteristics of naturally-occurring peptides by modifying and optimizing their structures. The modifications we make are designed to improve upon naturally occurring peptides so that their therapeutic benefit, duration of action, stability and/or convenience of use favorably compare to other treatment options. |
|
|
|
Post by neil36 on May 17, 2022 5:23:28 GMT -5
myehcs.com/v-go/Edwards Health Care, a medical device company, sells and promotes the V-Go device. They have seven locations in the U.S.
|
|
|
|
Post by hellodolly on May 17, 2022 5:24:32 GMT -5
|
|
|
|
Post by joeypotsandpans on May 17, 2022 5:41:31 GMT -5
It's a basal delivery system (with bolus feature) for T2 which combined with Afrezza would deliver a 24 hour solution which adds to the Mannkind reps toolbox when visiting endo offices. I'll leave it to Mike et al to explain their strategic expectations and reasoning behind the acquisition. Obviously he believes it will be complimentary and brings a new dimension to the marketability of a one stop solution for T2's. This will no doubt be presented and discussed at the upcoming conferences this month.
|
|
|
|
Post by hellodolly on May 17, 2022 5:54:21 GMT -5
It's a basal delivery system (with bolus feature) for T2 which combined with Afrezza would deliver a 24 hour solution which adds to the Mannkind reps toolbox when visiting endo offices. I'll leave it to Mike et al to explain their strategic expectations and reasoning behind the acquisition. Obviously he believes it will be complimentary and brings a new dimension to the marketability of a one stop solution for T2's. This will no doubt be presented and discussed at the upcoming conferences this month. Designed to be patient-friendly, V-Go is worn like a patch and eliminates the need for taking multiple daily shots. I see a connection between the two right in that sentence. As you said, I'm looking forward to their strategic expectations and how they intend to market this? |
|
|
|
Post by sayhey24 on May 17, 2022 6:11:39 GMT -5
Here is a pretty good article on V-Go. As Joey said its currently a T2 device. If combined with afrezza does it have a potential in the T1 community? If so it would be the "patch pump" Al used to talk about for T1s when using afrezza. If not this purchase is a head scratcher to me and I will need to better understand Mike's thinking. If T1 applicable with afrezza that could be pretty exciting and I look forward to the trial. www.verywellhealth.com/what-is-an-insulin-patch-pump-1087254#:~:text=Fast%2DActing%20Insulin-,Who%20Can%20Use%20V%2DGo,of%20basal%20insulin%20per%20day. |
|
|
|
Post by mango on May 17, 2022 6:34:00 GMT -5
What an exciting acquisition! MannKind has once again demonstrated a high level of self efficacy. Self efficacy is the belief an entity holds regarding their ability to affect a given circumstance or experience. It’s the belief that challenges are experiences that ought to be mastered rather than avoided—a belief that one has the power to affect the future through their choices. A high self efficacy manifests during challenging times—a reoccurring theme we have been witnessing as the MannKind Story unfolds. Another confident and complimentary decision executed by the Company to further expand the endocrine business, add tools to the sales force, increase revenue, and give a synergistic basal delivering medical device that can be paired nicely with Afrezza.
I’m looking forward to hearing MannKind’s strategic long term vision with this new acquisition.
|
|
|
|
Post by Clement on May 17, 2022 6:41:47 GMT -5
does the VGO device pierce the skin or does it operate like a transdermal patch without piercing?
Can Mannkind now offer a complete needle-free (or puncture-free) solution?
|
|
|
|
Post by Clement on May 17, 2022 6:48:51 GMT -5
DKK 161.3 million x .1413867 = $22.8 million USD in net sales of VGO and supplies in 2020 |
|
|
|
Post by mango on May 17, 2022 7:05:28 GMT -5
does the VGO device pierce the skin or does it operate like a transdermal patch without piercing? Can Mannkind now offer a complete needle-free (or puncture-free) solution? It’s a subcutaneous infusion so it uses a small needle. |
|
|
|
Post by cjm18 on May 17, 2022 7:05:42 GMT -5
David Kendall works for them.
Happy to see Mnkd is still dedicated to endocrinology.
Why are there sales milestones.
The insulin does not need to be refrigerated?
|
|
|
|
Post by mango on May 17, 2022 7:16:15 GMT -5
David Kendall works for them. Happy to see Mnkd is still dedicated to endocrinology. Why are there sales milestones. What does Kendall do for them? I don’t see him on their website. |
|
